NASDAQ:CGIXCancer Genetics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cancer Genetics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.03 -0.03 (-0.98 %) (As of 05/25/2020 04:00 PM ET) Add Compare Share Today's Range$3.01Now: $3.03▼$3.0850-Day Range$2.41MA: $3.04▼$3.4952-Week Range$1.92Now: $3.03▼$9.50Volume9,900 shsAverage Volume57,900 shsMarket Capitalization$6.36 millionP/E RatioN/ADividend YieldN/ABeta2.1 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Cancer Genetics, Inc. develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. The company's biopharma services offer companies with customized solutions for patient stratification and treatment selection through a suite of molecular- and biomarker-based testing services, customized assay development, and trial design consultation. Its clinical services provide information on diagnosis, prognosis, and predicting treatment outcomes of cancers to guide patient management. The company's discovery services offer the tools and testing methods for companies and researchers to identify and develop new compounds and molecular-based biomarkers for diagnostics and treatment of disease. It serves hospitals, cancer centers, clinics, academic institutions, and government-sponsored research institutions, as well as pharmaceutical and biotech companies performing clinical trials. The company collaborates with oncology centers and community-based hospitals to develop its proprietary diagnostic tests; and has collaboration with Cellaria to develop precision medicine tools and platform technologies to support the development of new cancer therapeutics. Cancer Genetics, Inc. was founded in 1999 and is based in Rutherford, New Jersey.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cancer Genetics. Previous Next 3.2 Community Rank Outperform VotesCancer Genetics has received 406 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCancer Genetics has received 224 “underperform” votes. (Add your “underperform” vote.)Community SentimentCancer Genetics has received 64.44% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cancer Genetics and other stocks. Vote “Outperform” if you believe CGIX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CGIX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCancer Genetics does not currently pay a dividend.Dividend GrowthCancer Genetics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cancer Genetics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 15.00% of the stock of Cancer Genetics is held by insiders.Percentage Held by InstitutionsOnly 10.38% of the stock of Cancer Genetics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Cancer Genetics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cancer Genetics is -0.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCancer Genetics has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.77 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CGIX Previous Symbol CUSIPN/A CIK1349929 Webwww.cancergenetics.com Phone201-528-9200Debt Debt-to-Equity Ratio0.02 Current Ratio0.99 Quick Ratio0.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$27.47 million Price / Sales0.23 Cash FlowN/A Price / Cash FlowN/A Book Value$7.37 per share Price / Book0.41Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-20,370,000.00 Net Margins-59.28% Return on Equity-139.59% Return on Assets-28.46%Miscellaneous Employees150 Outstanding Shares2,100,000Market Cap$6.36 million Next Earnings Date5/25/2020 (Estimated) OptionableOptionable NASDAQ:CGIX Rates by TradingView Receive CGIX News and Ratings via Email Sign-up to receive the latest news and ratings for CGIX and its competitors with MarketBeat's FREE daily newsletter. Cancer Genetics (NASDAQ:CGIX) Frequently Asked Questions How has Cancer Genetics' stock been impacted by COVID-19 (Coronavirus)? Cancer Genetics' stock was trading at $3.59 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CGIX stock has decreased by 15.6% and is now trading at $3.03. View which stocks have been most impacted by Coronavirus. When is Cancer Genetics' next earnings date? Cancer Genetics is scheduled to release its next quarterly earnings announcement on Monday, May 25th 2020. View our earnings forecast for Cancer Genetics. How were Cancer Genetics' earnings last quarter? Cancer Genetics Inc (NASDAQ:CGIX) announced its earnings results on Tuesday, April, 16th. The medical research company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.02. The medical research company earned $6.80 million during the quarter. Cancer Genetics had a negative return on equity of 139.59% and a negative net margin of 59.28%. View Cancer Genetics' earnings history. Has Cancer Genetics been receiving favorable news coverage? News coverage about CGIX stock has been trending very positive this week, according to InfoTrie. The research group rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Cancer Genetics earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutCancer Genetics. Are investors shorting Cancer Genetics? Cancer Genetics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 9,700 shares, an increase of 21.3% from the April 30th total of 8,000 shares. Based on an average daily volume of 53,600 shares, the short-interest ratio is currently 0.2 days. Approximately 0.5% of the company's shares are sold short. View Cancer Genetics' Current Options Chain. Who are some of Cancer Genetics' key competitors? Some companies that are related to Cancer Genetics include PotNetwork (POTN), Avant Diagnostics (AVDX), CBA Florida (CBAI), First Choice Healthcare Solutions (FCHS) and Aeon Global Health (AGHC). View all competitors. What other stocks do shareholders of Cancer Genetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cancer Genetics investors own include Actinium Pharmaceuticals (ATNM), Activision Blizzard (ATVI), Ford Motor (F), Gilead Sciences (GILD), Novavax (NVAX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Opko Health (OPK), Synergy Pharmaceuticals (SGYP) and Sorrento Therapeutics (SRNE). Who are Cancer Genetics' key executives? Cancer Genetics' management team includes the following people: Mr. John A. Roberts MBA, Pres, CEO, COO & Director (Age 60)Mr. Michael Glenn Miles, Chief Financial OfficerMr. Michael Brian McCartney, Chief Commercial OfficerMr. William Lansing Finger, Exec. VP of Precision Medicine & Biopharma SolutionsDr. Ralf Brandt, Pres of Discovery & Early Devel. Services (Age 56) What is Cancer Genetics' stock symbol? Cancer Genetics trades on the NASDAQ under the ticker symbol "CGIX." How do I buy shares of Cancer Genetics? Shares of CGIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Cancer Genetics' stock price today? One share of CGIX stock can currently be purchased for approximately $3.03. How big of a company is Cancer Genetics? Cancer Genetics has a market capitalization of $6.36 million and generates $27.47 million in revenue each year. Cancer Genetics employs 150 workers across the globe. What is Cancer Genetics' official website? The official website for Cancer Genetics is www.cancergenetics.com. How can I contact Cancer Genetics? Cancer Genetics' mailing address is 201 ROUTE 17 NORTH 2ND FLOOR, RUTHERFORD NJ, 07070. The medical research company can be reached via phone at 201-528-9200 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
